Related references
Note: Only part of the references are listed.Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study
Milena Sant et al.
EUROPEAN JOURNAL OF CANCER (2015)
Cancer beyond organ and tissue specificity: Next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers
D. Heim et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer
Suzy Davies et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2014)
Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
Karina Dahl Steffensen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
Soo Youn Bae et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies et al.
PLOS ONE (2012)
HER3 Overexpression as an Independent Indicator of Poor Prognosis for Patients with Curatively Resected Pancreatic Cancer
Toshiki Hirakawa et al.
ONCOLOGY (2011)
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Martin Koebel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue
Silvia Darb-Esfahani et al.
ENDOCRINE-RELATED CANCER (2009)
ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery
Glauco Baiocchi et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary
Martin Köbel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
Mikiko Hayashi et al.
CLINICAL CANCER RESEARCH (2008)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Koebel et al.
PLOS MEDICINE (2008)
ErbB-3 predicts survival in ovarian cancer
Berno Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma
CH Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Share Paper
